RNAi Screening for Therapeutic Targets in Human Malignancies

David   R.   Micklem; James   B.   Lorens

doi:10.2174/138920107783018426

Abstract

The advent of RNA interference (RNAi) based library screening approaches has sparked a surge in loss-of-function genetic screens. Several recent screens have aimed to identify novel regulators of cancer-related phenotypes. These employ various tumor cell types to model malignant cell functions and use different RNAi effector library approaches to reveal a cache of novel tumor regulators. This review surveys recent RNAi screens conducted in transformed human cells.

Keywords: RNA interference, genetic screen, cancer, therapeutic target

« Previous Next »

Rights & Permissions Print Cite

Current Pharmaceutical Biotechnology

Title: RNAi Screening for Therapeutic Targets in Human Malignancies

Volume: 8 Issue: 6

Author(s): David R. Micklem and James B. Lorens

Affiliation:

Keywords: RNA interference, genetic screen, cancer, therapeutic target

Abstract: The advent of RNA interference (RNAi) based library screening approaches has sparked a surge in loss-of-function genetic screens. Several recent screens have aimed to identify novel regulators of cancer-related phenotypes. These employ various tumor cell types to model malignant cell functions and use different RNAi effector library approaches to reveal a cache of novel tumor regulators. This review surveys recent RNAi screens conducted in transformed human cells.

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Micklem R. David and Lorens B. James, RNAi Screening for Therapeutic Targets in Human Malignancies, Current Pharmaceutical Biotechnology 2007; 8 (6) . https://dx.doi.org/10.2174/138920107783018426